Prosecution Insights
Prosecution Insights
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.4% | +37.9% |
| SAMSELL, RILLA MARIE | 1 | 72.0% | +15.0% |
| CLARK, AMY LYNN | 1 | 39.1% | +30.9% |
| SAEED, ALI S | 1 | 31.2% | +34.3% |
| COPPINS, JANET L | 1 | 72.9% | +25.5% |
| ARNOLD, ERNST V | 1 | 48.1% | +12.9% |
| MOSS, NATALIE M | 1 | 30.9% | +16.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 49d overdue |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | CLARK, AMY LYNN | 83d |
| 18231114 | AUTOIMMUNE THERAPY | COPPINS, JANET L | 83d |
| 18573362 | TREATMENT FOR AUTOIMMUNE DISEASES | MCMILLIAN, KARA RENITA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 49d overdue |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 8d overdue |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | SAMSELL, RILLA MARIE | 20d |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | SAEED, ALI S | 76d |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | CLARK, AMY LYNN | 83d |
| 18231114 | AUTOIMMUNE THERAPY | COPPINS, JANET L | 83d |
| 18573362 | TREATMENT FOR AUTOIMMUNE DISEASES | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1623 | 1 |
| 1624 | 1 |
| 1616 | 1 |
| 1613 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573362 | TREATMENT FOR AUTOIMMUNE DISEASES | MCMILLIAN, KARA RENITA | 1623 | §103§112Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | SAMSELL, RILLA MARIE | 1624 | DP | Final Rejection | 20d | Pending | Dec 21, 2023 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | CLARK, AMY LYNN | 1628 | §102§103§112 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | SAEED, ALI S | 1616 | §103§112DPOther | Non-Final OA | 76d | Pending | Dec 20, 2023 |
| 18231114 | AUTOIMMUNE THERAPY | COPPINS, JANET L | 1628 | §103§112 | Final Rejection | 83d | Pending | Aug 07, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | ARNOLD, ERNST V | 1613 | §103§112 | Non-Final OA | 49d overdue | Pending | Jul 21, 2023 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | 8d overdue | Pending | Sep 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial